Seikagaku reported FY 4Q19 orthopedic revenue of ¥2,555.5 million (USD $23.1 million), -22.4% vs. 4Q18, with full-year FY19 revenue of USD $130.4 million, +4.7%. The company’s sales of ARTZ in Japan were down due to the overall contraction of the domestic market as well as continuing price pressure from NHI drug price reductions. Seikagaku continued to gain momentum in the U.S. with its Gel-One single-injection viscosupplement through the combination of reimbursement wins and competitive account conversions. The company anticipates declining domestic and international sales due to COVID-19 in fiscal year 2020.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
4Q19
4Q18
$ Chg
% Chg
Orthobiologics
$23.1
$29.7
($6.6)
(22.4%)
FY19
FY18
$ Chg
% Chg
Orthobiologics
$130.4
$124.6
$5.8
4.7%
Geographic Sales
4Q19
4Q18
$ Chg
% Chg
Domestic (Japan)
$9.6
$14.0
($4.4)
(31.5%)
International
$13.5
$15.7
($2.2)
(14.3%)
Total
$23.1
$29.7
($6.6)
(22.4%)
FY19
FY18
$ Chg
% Chg
Domestic (Japan)
$59.3
$61.4
($2.1)
(3.4%)
International
$71.1
$63.2
$7.9
12.5%
Total
$130.4
$124.6
$5.8
4.7%
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Seikagaku reported FY 4Q19 orthopedic revenue of ¥2,555.5 million (USD $23.1 million), -22.4% vs. 4Q18, with full-year FY19 revenue of USD $130.4 million, +4.7%. The company’s sales of ARTZ in Japan were down due to the overall contraction of the domestic market as well as continuing price pressure from NHI drug price reductions. Seikagaku...
Seikagaku reported FY 4Q19 orthopedic revenue of ¥2,555.5 million (USD $23.1 million), -22.4% vs. 4Q18, with full-year FY19 revenue of USD $130.4 million, +4.7%. The company’s sales of ARTZ in Japan were down due to the overall contraction of the domestic market as well as continuing price pressure from NHI drug price reductions. Seikagaku continued to gain momentum in the U.S. with its Gel-One single-injection viscosupplement through the combination of reimbursement wins and competitive account conversions. The company anticipates declining domestic and international sales due to COVID-19 in fiscal year 2020.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
4Q19
4Q18
$ Chg
% Chg
Orthobiologics
$23.1
$29.7
($6.6)
(22.4%)
FY19
FY18
$ Chg
% Chg
Orthobiologics
$130.4
$124.6
$5.8
4.7%
Geographic Sales
4Q19
4Q18
$ Chg
% Chg
Domestic (Japan)
$9.6
$14.0
($4.4)
(31.5%)
International
$13.5
$15.7
($2.2)
(14.3%)
Total
$23.1
$29.7
($6.6)
(22.4%)
FY19
FY18
$ Chg
% Chg
Domestic (Japan)
$59.3
$61.4
($2.1)
(3.4%)
International
$71.1
$63.2
$7.9
12.5%
Total
$130.4
$124.6
$5.8
4.7%
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
